This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
12 Nov 2015

Cellular Biomedicine Group opens new GMP facility in Beijing

Four independent production lines to support clinical batch production and commercial scale manufacturing.

Cellular Biomedicine Group has announced the opening of its new state-of-the-art facility in the PKUCare Industrial Park, Changping District, Beijing, China. Eight hundred square meters of the 1,400 square meter site has been equipped with four independent production lines to support clinical batch production and commercial scale manufacturing. Designed and built to GMP standards, the facility has been certified by the Beijing Institute for Drug Control, accredited bodies of the China National Accreditation Service (CNAS) and China Metrology Accreditation (CMA). With this expansion into Beijing, the company now operates three GMP facilities in China that will house nine independent production lines with the capacity to host more than 200,000 individual cell sources.

“We feel this is the opportune time for this expansion into Beijing as we prepare for increasing manufacturing demands to supply cell therapy materials for more research and clinical trials from our immuno-oncology, especially CAR-T therapy, and mesenchymal progenitor cell (haMPC) programs,” said Dr Richard L. Wang, Chief Operating Officer for the company. Our multi-national team of seasoned scientists is proud to see the implementation of our vertically integrated research and development and production systems in several locations. With patented processes and technologies applied to every step of our cellular medicine platform spanning sample collection and processing, cell expansion, banking, shipping and application, we are able to deliver consistent quality measures across China, which we believe will better serve our patient population in the future.”

Related News